Biopôle is a life sciences campus in Lausanne, Switzerland, boasting a renowned community of companies, academic institutions and research organisations, as well as state-of-the-art laboratories, office buildings and amenities. The site is home to more than 120 companies and organisations, including the head offices of multinationals, start-ups, SMEs, clinical development teams and technology and service providers. It also hosts more than 25 world-renowned research groups.
The Office for Economic Affairs and Innovation (SPEI) supports companies that are located in the State of Vaud, especially those involved in the sectors of advanced technology and industry. SPEI advises entrepreneurs and puts them in contact with organizations that are appropriate to their specific needs. SPEI can also provide direct financial support.
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.
For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.
PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures’ services include:
M&A (divestments, mergers, acquisitions, and strategic transactions)
Licensing (in and out licensing)
Strategy (commercialisation, deal strategy, due diligence, market entry)
Valuations (licensing, M&A and fundraising)
Pricing and Market Access
PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Asia-Pacific.
PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).